Page 88 - Priority Review News Today

LONDON (dpa-AFX) - British biopharma company GSK plc (GSK, GSK.L) announced Wednesday that the US Food and Drug Administration has accepted a Biologics License Application or BLA and granted Priority

~ Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation ~~ U.S. and European pre-approval inspections of Company's

The FDA has accepted for Priority Review the NDA for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism.

GSK plc (NYSE:NYSE:GSK) Q3 2022 Earnings Conference Call November 02, 2022, 08:00 ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director...

Pfizer said that it plans to submit an application for approval by the U.S. Food and Drug Administration (FDA) by the end of the year.

Abhijeet Sinha of Lonza Small Molecules, exemplifies the imperative of solving small molecule drug development challenges early.

31.10.2022 - - PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN, Denmark, Oct. 31, 2022 (GLOBE NEWSWIRE) -  Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration ... Seite 1

NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...

28.10.2022 - NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) - Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic ... Seite 1

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary, unaudited financial...